Announcements

    Drinks

      THURSDAY, 25/01/2018 - Scope Ratings AG
      Download PDF

      Sanofi ratings unaffected by Bioverativ acquisition

      Scope believes that the recently announced USD 11.6 bn acquisition of US-based biotech company Bioverativ is not a challenge for Sanofi’s credit rating.

      While the transaction, which is still pending regulatory approval, is fully funded by a combination of cash and additional debt, its likely negative impact on Sanofi’s financial risk profile is of insignificant relevance in the context of the ratings. This is not to say credit metrics will not deteriorate in 2018 compared to the previous year, but Scope believes that the likely deterioration will not be strong enough to justify a negative rating action.

      Scope had stated in its last outlook statement that the rating reflects Sanofi being able to maintain the following Scope-adjusted credit metrics: funds from operations to debt of 60%, and free operating cash flow to debt of at least 40%. The agency does not believe that the acquisition of Bioverativ is likely to endanger these thresholds meaningfully and can thus maintain the ratings.

      Related news

      Show all
      Scope downgrades Masterplast Nyrt. issuer rating to B/Negative from B+/UR for a possible downgrade

      28/2/2024 Rating announcement

      Scope downgrades Masterplast Nyrt. issuer rating to ...

      Scope has completed a monitoring review for ITK Holding Zrt.

      27/2/2024 Monitoring note

      Scope has completed a monitoring review for ITK Holding Zrt.

      Scope affirms Fnac Darty S.A.’s issuer rating at BBB and revises the Outlook to Stable from Negative

      23/2/2024 Rating announcement

      Scope affirms Fnac Darty S.A.’s issuer rating at BBB and ...

      Scope affirms issuer rating of Posten Bring at A and revises Outlook to Stable

      22/2/2024 Rating announcement

      Scope affirms issuer rating of Posten Bring at A and revises ...

      Scope downgrades Pannonia Bio’s issuer rating to BB and maintains the Negative Outlook

      21/2/2024 Rating announcement

      Scope downgrades Pannonia Bio’s issuer rating to BB and ...

      Scope Ratings has affirmed the B+/Stable issuer rating of Biggeorge Property Nyrt.

      19/2/2024 Rating announcement

      Scope Ratings has affirmed the B+/Stable issuer rating of ...